Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 6/20 | 0.62 |
| ▸ | CCKBR | P32239 | 2/20 | 0.62 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.61 |
| ▸ | NMBR | P28336 | 2/20 | 0.61 |
| ▸ | GRPR | P30550 | 2/20 | 0.61 |
| ▸ | GCGR | P47871 | 4/20 | 0.61 |
| ▸ | GIPR | P48546 | 1/20 | 0.61 |
| ▸ | CALCR | P30988 | 4/20 | 0.61 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.60 |
| ▸ | F2 | P00734 | 3/20 | 0.59 |
| ▸ | NPY1R | P25929 | 1/20 | 0.59 |
| ▸ | NPY2R | P49146 | 1/20 | 0.59 |
| ▸ | NPY4R | P50391 | 1/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30767709 | 0.94 | GLP1R (0.61) | GLP1RCCKBRC5AR1NMBRGRPR | |
| SCHEMBL29811055 | 0.94 | GLP1R (0.68) | GLP1RCCKBRNMBRGRPRGCGR | |
| SCHEMBL30767696 | 0.93 | GLP1R (0.60) | GLP1RCCKBRC5AR1NMBRGRPR | |
| SCHEMBL30767712 | 0.91 | F2 (0.58) | GLP1RCCKBRC5AR1NMBRGRPR | |
| SCHEMBL30767699 | 0.90 | F2 (0.58) | GLP1RCCKBRC5AR1NMBRGRPR | |
| SCHEMBL30495677 | 0.90 | NPY1R (0.72) | GLP1RCCKBRGCGRGIPRCALCR | |
| SCHEMBL30537029 | 0.90 | GLP1R (0.72) | GLP1RCCKBRC5AR1CALCRNPY1R | |
| SCHEMBL31000931 | 0.89 | GLP1R (0.70) | GLP1RCCKBRNMBRGRPRGCGR | |
| SCHEMBL31174212 | 0.89 | C5AR1 (0.64) | GLP1RCCKBRC5AR1NMBRGRPR | |
| SCHEMBL30607279 | 0.89 | NPY1R (0.68) | GLP1RCCKBRC5AR1NMBRGRPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629409-B2 | Vaccine | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2026-05-19 | — | — | US | disclosed |
| US-20240226261-A9 | VACCINE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-07-11 | — | — | US | disclosed |
| US-20240131136-A1 | VACCINE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-04-25 | — | — | US | disclosed |
| US-11844828-B2 | Vaccine | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-12-19 | — | — | US | disclosed |
| US-20230248816-A9 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-08-10 | — | — | US | disclosed |
| US-20230066762-A1 | IMMUNOGENIC COMPOSITION | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-03-02 | — | — | US | disclosed |
| US-20220288190-A1 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-09-15 | — | — | US | disclosed |
| US-20220152182-A1 | VACCINE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-05-19 | — | — | US | disclosed |
| US-11266731-B2 | Vaccine | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288190-A1 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | CFD, PEPD, SERPINA6 | GLP1R 2107/4885CCKBR 1367/4885C5AR1 403/4885 |
| US-20230248816-A9 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | CFD, PEPD, SERPINA6 | GLP1R 2107/4885CCKBR 1367/4885C5AR1 403/4885 |
| US-12629409-B2 | Vaccine | MRPL21, STT3B, CD47 | GLP1R 1475/4885CCKBR 2768/4885C5AR1 1431/4885 |
| US-20230066762-A1 | IMMUNOGENIC COMPOSITION | CXCL10, CCL2, CCL11 | GLP1R 2834/4885CCKBR 1914/4885C5AR1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.